Last updated on September 2018

Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne


Brief description of study

The study is designed primarily to assess preliminary efficacy and safety of CJM112 in patients with moderate to severe inflammatory acne and to determine if CJM112 has an adequate clinical profile for further clinical development. In addition, sustainability of response and dose relationship will be explored.

Clinical Study Identifier: NCT02998671

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Culver City, CA United States

Novartis Pharmaceuticals

Novartis Investigative Site
Hershey, PA United States

Novartis Pharmaceuticals

Novartis Investigative Site
Austin, TX United States

Novartis Pharmaceuticals

Novartis Investigative Site
Berlin, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Bonn, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Dresden, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Frankfurt, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Muenster, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Bergen op Zoom, Netherlands

Novartis Pharmaceuticals

Novartis Investigative Site
Groningen, Netherlands

Novartis Pharmaceuticals

Novartis Investigative Site
Leiden, Netherlands

Novartis Pharmaceuticals

Novartis Investigative Site
Sacramento, CA United States

Novartis Pharmaceuticals

Novartis Investigative Site
High Point, NC United States

Novartis Pharmaceuticals

Novartis Investigative Site
Pommelsbrunn, Germany